ClinicalTrials.gov
public full text
Public Domain
Gene Therapy in Patients With Mucopolysaccharidosis Disease
This study investigated the safety and efficacy of gene therapy approaches for Mucopolysaccharidosis type VI disease caused by the deficiency of arylsulfatase B (ARSB) enzyme. The aim of the study is to evaluate the safety and efficacy of the treatment.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- An Extension Study of JR-171-101 Study in Patients With Mucopolysaccharidosis Type I (MPS I)#910821
- An Open-label Phase I/II Study of JR-446 in Mucopolysaccharidosis Type IIIB#1139194
- Extension Study of Intrathecal Enzyme Replacement Therapy for MPS I#1029856
- Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of rhHNS Administration Via an IDDD in Pediatric Patients With Early Stage MPS IIIA Disease#915132
- Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation#884164
Record · ID 1095745
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive